Medication Guide
Now approved for Major Depressive Disorderas an add-on to an antidepressant
Actor portrayal.
SIGNIFICANT RELIEF FROM
DEPRESSION SYMPTOMS IN:
*CAPLYTA is FDA-approved to treat adults with major depressive disorder used along with an antidepressant.
†CAPLYTA is proven to deliver significant symptom relief in adults with bipolar I or bipolar II depression. CAPLYTA can be taken alone or with lithium or valproate.
‡Based on total prescriptions dispensed across approved indications since CAPLYTA was FDA‑approved in 2019.
MDD indication was approved in November 2025.
ELIGIBLE§ PATIENTS
MAY PAY AS LITTLE AS
AS LITTLE AS
ANTIDEPRESSANT
§This offer is valid for eligible new or existing patients who are filling a prescription for CAPLYTA. Eligible patients must be 18 years of age or older, residents of the US or its territories where CAPLYTA is available and have a valid prescription for CAPLYTA for a Food & Drug Administration approved indication. This Savings program is valid ONLY for patients with private commercial insurance and NOT valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs. Offer is only good at participating retail pharmacies. Offer is not transferable, is not insurance, has no cash value, and may not be used in combination with other offers. Void if prohibited by law, taxed, or restricted.
All participants are responsible for reporting the receipt of all Program benefits as required by their insurance provider. No party may seek reimbursement for all or any of the benefit received through this Program. Johnson & Johnson reserves the right to rescind, revoke or amend the Program without notice at any time. Additional eligibility criteria apply.
Click here for full Eligibility Criteria and Terms & Conditions.
||Maximum savings limit applies; patient out-of-pocket expense may vary.
Prepare for your next visit
Answer these questions to HELP guide your Conversation about CAPLYTA
Build Your Doctor Discussion Guide